The 36-month beta value for BMRA is at 0.39. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BMRA is 2.30M, and currently, shorts hold a 1.87% of that float. The average trading volume for BMRA on May 23, 2025 was 40.95K shares.
BMRA) stock’s latest price update
Biomerica Inc (NASDAQ: BMRA)’s stock price has dropped by -4.56 in relation to previous closing price of 3.51. Nevertheless, the company has seen a loss of -8.75% in its stock price over the last five trading days. globenewswire.com reported 2025-05-22 that IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ: BMRA), an innovator in diagnostic-guided therapy, today announced compelling real-world results demonstrating the effectiveness of its inFoods® IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes.
BMRA’s Market Performance
Biomerica Inc (BMRA) has experienced a -8.75% fall in stock performance for the past week, with a -8.47% drop in the past month, and a -50.09% drop in the past quarter. The volatility ratio for the week is 2.60%, and the volatility levels for the past 30 days are at 3.21% for BMRA. The simple moving average for the past 20 days is -6.24% for BMRA’s stock, with a -6.39% simple moving average for the past 200 days.
Analysts’ Opinion of BMRA
Many brokerage firms have already submitted their reports for BMRA stocks, with Colliers Securities repeating the rating for BMRA by listing it as a “Buy.” The predicted price for BMRA in the upcoming period, according to Colliers Securities is $13 based on the research report published on November 10, 2020 of the previous year 2020.
B. Riley FBR Inc., on the other hand, stated in their research note that they expect to see BMRA reach a price target of $7.50. The rating they have provided for BMRA stocks is “Buy” according to the report published on January 04th, 2018.
BMRA Trading at -19.22% from the 50-Day Moving Average
After a stumble in the market that brought BMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.03% of loss for the given period.
Volatility was left at 3.21%, however, over the last 30 days, the volatility rate increased by 2.60%, as shares sank -10.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.67% lower at present.
During the last 5 trading sessions, BMRA fell by -8.75%, which changed the moving average for the period of 200-days by +52.22% in comparison to the 20-day moving average, which settled at $3.57. In addition, Biomerica Inc saw 39.54% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for BMRA
Current profitability levels for the company are sitting at:
- -0.9 for the present operating margin
- 0.13 for the gross margin
The net margin for Biomerica Inc stands at -0.85. The total capital return value is set at -0.89. Equity return is now at value -72.70, with -54.75 for asset returns.
Based on Biomerica Inc (BMRA), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -7.78.
Currently, EBITDA for the company is -5.99 million with net debt to EBITDA at 0.54. When we switch over and look at the enterprise to sales, we see a ratio of 1.06. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.76.
Conclusion
In conclusion, Biomerica Inc (BMRA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
